Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.
| Revenue (TTM) | $3.19B |
| Gross Profit (TTM) | $2.29B |
| EBITDA | $693.30M |
| Operating Margin | 22.50% |
| Return on Equity | 28.90% |
| Return on Assets | 11.40% |
| Revenue/Share (TTM) | $45.72 |
| Book Value | $22.76 |
| Price-to-Book | 6.86 |
| Price-to-Sales (TTM) | 3.19 |
| EV/Revenue | 3.514 |
| EV/EBITDA | 15.70 |
| Quarterly Earnings Growth (YoY) | 63.70% |
| Quarterly Revenue Growth (YoY) | 19.20% |
| Shares Outstanding | $69.37M |
| Float | $69.08M |
| % Insiders | 0.33% |
| % Institutions | 105.48% |
Volatility is currently expanding
Insulet NASDAQ: PODD reported third-quarter revenue of $842 million, up 19.2% on a reported basis and 19.6% on a constant-currency basis, as international growth outpaced the company's plans and U.S. performance landed within its guidance range.
Insulet Corporation (PODD) Q3 2026 Earnings Call Transcript
While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Insulet (PODD) came out with quarterly earnings of $1.99 per share, beating the Zacks Consensus Estimate of $1.59 per share. This compares to earnings of $1.24 per share a year ago.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. full market release of Omnipod Discover™, a web-based data platform designed for Omnipod 5 users, their caregivers, and healthcare providers (HCPs). Omnipod Discover turns critical diabetes data into clear visualizations and personalized insights, giving people with diabetes and their HCPs a shared understanding of.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Insulet NASDAQ: PODD Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated diabetes markets, while addressing elevated early attrition among certain Type 2 diabetes customers.
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Thursday, September 24, 2026, at 12:30 p.m. (Eastern Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PODD and any ticker you trade — then tracks every position and per-strategy win rate.
